Closed-loop therapy in older adults with type 1 diabetes: hypoglycaemia benefits and risk stratification
- PMID: 36098315
- DOI: 10.1016/S2666-7568(22)00092-7
Closed-loop therapy in older adults with type 1 diabetes: hypoglycaemia benefits and risk stratification
Conflict of interest statement
SAM reports support for research from Medtronic, speaker honoraria from Eli Lilly, Roche, and Sanofi, and has served on an advisory board for Medtronic. ST reports non-financial support from Abbott Diabetes.
Comment in
-
Closed-loop therapy in older adults with type 1 diabetes: hypoglycaemia benefits and risk stratification - Authors' reply.Lancet Healthy Longev. 2022 Jun;3(6):e379. doi: 10.1016/S2666-7568(22)00112-X. Epub 2022 Jun 9. Lancet Healthy Longev. 2022. PMID: 36098316 No abstract available.
Comment on
-
Can technology improve the management of older adults with type 1 diabetes? Yes, but….Lancet Healthy Longev. 2022 Mar;3(3):e120-e121. doi: 10.1016/S2666-7568(22)00032-0. Lancet Healthy Longev. 2022. PMID: 36098285 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
